Tetrahydrobiopterin monotherapy for phenylketonuria patients with common mild mutations

The effect of tetrahydrobiopterin (BH4) administration was studied in three infants with BH4 responsive phenylalanine hydroxylase (PAH) deficiency by correlating different oral BH4 doses with plasma phenylalanine levels under defined protein intake.